Market Overview

BioCryst Reports Filing for Peramivir NDA Supported by BARDA/HHS Funding

Related BCRX
BioCryst Pharmaceuticals, Inc. Announces RAPIVAB Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting
BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.8 million contract to enable completion of a New Drug Application (NDA) filing for intravenous (i.v.) peramivir. BioCryst is seeking an indication for the treatment of acute uncomplicated influenza and expects to submit the peramivir NDA by the end of 2013.

On June 28, BioCryst completed a pre-NDA meeting with the FDA regarding peramivir. BioCryst reached agreement with FDA regarding all requirements for a complete NDA submission.

Posted-In: News

 

Related Articles (BCRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters